Nanollose Limited (NC6.AX)
AUD 0.02
(0.0%)
AUD 0.02
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 465.64 Thousand AUD | 156.4% |
| 2023 | 181.6 Thousand AUD | 0.05% |
| 2022 | 181.5 Thousand AUD | -64.26% |
| 2021 | 507.83 Thousand AUD | 114.5% |
| 2020 | 236.75 Thousand AUD | 49.64% |
| 2019 | 158.21 Thousand AUD | -1.34% |
| 2018 | 160.37 Thousand AUD | 20.0% |
| 2017 | 133.65 Thousand AUD | 509.05% |
| 2016 | 21.94 Thousand AUD | 37.15% |
| 2015 | 16 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 465.64 Thousand AUD | 156.4% |
| 2024 Q2 | 768.92 Thousand AUD | 323.4% |
| 2024 Q4 | 465.64 Thousand AUD | -39.44% |
| 2023 Q2 | 172.11 Thousand AUD | 0.0% |
| 2023 FY | 181.6 Thousand AUD | 0.05% |
| 2023 Q4 | 181.6 Thousand AUD | 0.0% |
| 2022 FY | 181.5 Thousand AUD | -64.26% |
| 2022 Q2 | 164.78 Thousand AUD | 0.0% |
| 2022 Q4 | 181.5 Thousand AUD | 0.0% |
| 2021 Q2 | 140.5 Thousand AUD | 0.0% |
| 2021 FY | 507.83 Thousand AUD | 114.5% |
| 2021 Q4 | 507.83 Thousand AUD | 0.0% |
| 2020 Q4 | 236.75 Thousand AUD | 0.0% |
| 2020 FY | 236.75 Thousand AUD | 49.64% |
| 2020 Q2 | 144.84 Thousand AUD | 0.0% |
| 2019 Q4 | 158.21 Thousand AUD | 0.0% |
| 2019 FY | 158.21 Thousand AUD | -1.34% |
| 2019 Q2 | 139.82 Thousand AUD | 0.0% |
| 2018 Q4 | 160.37 Thousand AUD | 0.0% |
| 2018 FY | 160.37 Thousand AUD | 20.0% |
| 2018 Q2 | 142 Thousand AUD | 0.0% |
| 2017 Q1 | - AUD | 0.0% |
| 2017 FY | 133.65 Thousand AUD | 509.05% |
| 2017 Q4 | 188.65 Thousand AUD | 0.0% |
| 2017 Q3 | 188.65 Thousand AUD | 0.0% |
| 2016 FY | 21.94 Thousand AUD | 37.15% |
| 2015 FY | 16 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 4.22 Million AUD | 88.99% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -51.75% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 95.023% |
| Biome Australia Limited | 5.37 Million AUD | 91.334% |
| Patrys Limited | 691.36 Thousand AUD | 32.649% |
| Orthocell Limited | 22.08 Million AUD | 97.891% |
| Imugene Limited | 33.14 Million AUD | 98.595% |
| Noxopharm Limited | 1.28 Million AUD | 63.865% |
| PYC Therapeutics Limited | 10.18 Million AUD | 95.428% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 96.363% |
| Prescient Therapeutics Limited | 2.32 Million AUD | 79.977% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | 71.361% |
| Cynata Therapeutics Limited | 1.17 Million AUD | 60.237% |
| CSL Limited | 27.88 Billion AUD | 99.998% |
| Arovella Therapeutics Limited | 2.05 Million AUD | 77.359% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -26.38% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 98.344% |
| Starpharma Holdings Limited | 8.69 Million AUD | 94.647% |
| Memphasys Limited | 5.59 Million AUD | 91.674% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -7.88% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -443.449% |
| Amplia Therapeutics Limited | 3.42 Million AUD | 86.412% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | 87.523% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | 55.467% |
| Race Oncology Limited | 1.91 Million AUD | 75.703% |
| Nyrada Inc. | 855.63 Thousand AUD | 45.579% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 99.813% |
| Dimerix Limited | 13.89 Million AUD | 96.648% |
| PharmAust Limited | 896.6 Thousand AUD | 48.066% |
| Immutep Limited | 10.97 Million AUD | 95.759% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 94.411% |
| Alterity Therapeutics Limited | 5.42 Million AUD | 91.418% |
| BTC Health Limited | 203.94 Thousand AUD | -128.315% |
| Acrux Limited | 5.68 Million AUD | 91.812% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 98.911% |
| Biotron Limited | 737.5 Thousand AUD | 36.863% |
| Tissue Repair Ltd | 1.35 Million AUD | 65.531% |
| AdAlta Limited | 3.54 Million AUD | 86.856% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 98.958% |
| Hexima Limited | 248.67 Thousand AUD | -87.253% |
| AnteoTech Limited | 4.07 Million AUD | 88.574% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | 87.009% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 97.07% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | 50.545% |
| Actinogen Medical Limited | 1.61 Million AUD | 71.174% |
| Immuron Limited | 2.84 Million AUD | 83.607% |
| Argenica Therapeutics Limited | 2.42 Million AUD | 80.812% |